Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.
Eli Lilly unexpectedly lowered ... Meanwhile, its non-weight loss drug portfolio is also growing nicely. From a valuation perspective, Lilly trades at a forward price-to-earnings (P/E) of ...
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro. The drugmaker ...
Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...
Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the ...
Get Wall Street's Hottest Chart Every Morning Medicare drug plans can now cover Eli Lilly And Co's LLY popular ... or other insurance plans for weight loss. In December, the FDA approved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback